Dendritic cell activation kinetics and cancer immunotherapy.

In a recent paper published in The Journal of Immunology , Watanabe and colleagues ([1][1]) report on the impact of dendritic cell (DC) activation kinetics on the in vivo priming of Ag-specific T lymphocytes. Thus, the authors focus on a central issue in DC-based immunotherapy, which has already